ArticleCancers2020
Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Fibromyxoid Nephrogenic Adenoma Mimicking Renal Cell Carcinoma: A Diagnostic Pitfall in Fine-Needle Aspiration Cytology.Diagnostic cytopathology · 2026Article
- Hyalinizing Clear Cell Carcinoma of the Lung With Uncommon Distant Cutaneous Metastasis and Aggressive Clinical Course.Journal of cutaneous pathology · 2026Article
- Synergistic role of TFEB/TFE3 and mTORC1 in kidney cystogenesis and tumorigenesis.Cell death and differentiation · 2026Article
- Metastatic renal cell carcinoma to the thyroid gland with tracheal invasion: A case report.Radiology case reports · 2026Article
- Adenocarcinoma of the Rete Testis With PI3K/AKT/mTOR Pathway Alteration and a Gene Expression Profile Resembling Papillary Renal Cell Carcinoma: A Case Report.Case reports in urology · 2026Article
- Article
- Prognostic Role of Global DNA Methylation in Renal Cancer Reveals Decitabine Treatment Benefit.Current medicinal chemistry · 2026Article
- Review
- DNA Methylation-Based Classification of Kidney Neoplasms.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
- Article
- Iterative refinement and goal articulation to optimize large language models for clinical information extraction.NPJ digital medicine · 2025Article
- Thyroid-like Follicular Carcinoma of the Kidney: The Follicles Are out There in the Kidney-Now What?Diagnostics (Basel, Switzerland) · 2025Article
- A modified Delphi consensus statement on the role of biopsy in small renal masses.BJUI compass · 2025Article
- Prompts to Table: Specification and Iterative Refinement for Clinical Information Extraction with Large Language Models.medRxiv : the preprint server for health sciences · 2025Article
- LINC01322 may serve as a potential diagnostic marker for advanced stage tumors in renal cell carcinoma patients eligible for total nephrectomy.Biochemistry and biophysics reports · 2024Article
- Primary extrarenal papillary type II renal cell carcinoma presenting as a pelvic mass: a case report and review of the literature.Journal of surgical case reports · 2024Article
- Immunotherapy Applications for Thymine Dimers and WT1 Antigen in Renal Cancers: A Comparative Statistical Analysis.Journal of personalized medicine · 2024Article
- Comprehensive proteogenomic characterization of rare kidney tumors.Cell reports. Medicine · 2024Article
- Detection of two synchronous histologically different renal cell carcinoma subtypes in the same kidney: a case report and review of the literature.Journal of medical case reports · 2024Review
- Diagnostic Biomarkers in Renal Cell Tumors According to the Latest WHO Classification: A Focus on Selected New Entities.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In recent years, renal epithelial tumors have been among the fastest reclassifying tumors, requiring updates to the tumor classification system. Nonetheless, immunohistochemistry (IHC) remains the most widely used tool for renal epithelial tumors. In this proposal, we aimed to create the most efficient IHC panel for categorizing the diverse subtypes of renal tumors, and to find out more specific immunohistochemical results in each subtype or each antibody. A total of 214 renal tumors were analyzed using 10 possible IHC markers to differentiate subtypes, including three major renal cell carcinoma (RCC) subtypes, clear-cell type (50 cases), papillary type (50 cases), and chromophobe type (20 cases), and minor subtypes (MiT RCC, 13 cases; collecting duct carcinoma, 5 cases; and oncocytoma, 10 cases). A triple immunomarker (cytokeratin 7 (CK7)-carbonic anhydrase IX (CAIX)- alpha-methylacyl-CoA racemase (AMACR)) panel is useful in particular high-grade clear-cell tumors. If IHC remains ambiguous, the use of an adjunctive panel can be suggested, including CD10, epithelial membrane antigen, cathepsin K, c-kit, hepatocyte nuclear factor 1-β, and E-cadherin. For an efficient immunohistochemical strategy for subtyping of RCC, we conclude that the CK7-CAIX-AMACR panel is the best primary choice for screening subtyping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.